ABOUT RITUXIMAB

Truqap is often a kinase inhibitor that works by blocking pathways that help the most cancers cells survive and expand, so decreases most cancers progress. Truqap is from a category of medicines known as an AKT inhibitor. Truqap received FDA approval on November 17, 2023, after optimistic benefits within the CAPItello-291 Period III demo. How effec